AMENDMENT NO. 4 TO CONVERTIBLE PROMISSORY NOTE AND AMENDMENT TO LETTER AGREEMENTConvertible Promissory Note and Amendment to Letter Agreement • October 2nd, 2023 • Seelos Therapeutics, Inc. • Pharmaceutical preparations • New York
This Amendment No. 4 to Convertible Promissory Note and Amendment to Letter Agreement (this “Amendment”) is effective as of September 30, 2023 (the “Effective Date”), by and between Seelos Therapeutics, Inc., a Nevada corporation (the “Company”), and Lind Global Asset Management V, LLC, a Delaware limited liability company (together with its successors and representatives, the “Holder”) and amends: (i) that certain Convertible Promissory Note No. 1 in the initial principal amount of $22,000,000 and due November 23, 2024, issued by the Company to the Holder on November 23, 2021, as amended on December 10, 2021, on February 8, 2023 and on May 19, 2023 (as so amended, the “Note”), and (ii) that certain letter agreement with the subject line “Convertible Promissory Note”, dated September 21, 2023, by and between the Company and the Holder (the “Letter Agreement”). Capitalized terms used but not otherwise defined herein shall have the meaning ascribed to them in the Note or that certain Sec
